Sample Size Calculations In Clinical Research

INTRODUCTION Regulatory Requirement Basic Considerations Procedures for Sample Size Calculation Aims and Structure of the Book CONSIDERATIONS PRIOR TO SAMPLE SIZE CALCULATION Confounding and Interaction One-Sided Test Versus Two-Sided Test Crossover Design Versus Parallel Design Subgroup/Interim Analyses Data Transformation Practical Issues COMPARING MEANS One-Sample Design Two-Sample Parallel Design Two-Sample Crossover Design Multiple-Sample One-Way ANOVA Multiple-Sample Williams Design Practical Issues LARGE SAMPLE TESTS FOR PROPORTIONS One-Sample Design Two-Sample Parallel Design Two-Sample Crossover Design One-Way Analysis of Variance Williams Design Relative Risk - Parallel Design Relative Risk - Crossover Design Practical Issues EXACT TESTS FOR PROPORTIONS Binomial Test Fisher's Exact Test Optimal Multiple-Stage Designs for Single Arm Trials Flexible Designs for Multiple-Arm Trials Remarks TESTS FOR GOODNESS-OF-FIT AND CONTINGENCY TABLES Tests for Goodness-of-Fit Test for Independence -Single Stratum Test for Independence -Multiple Strata Test for Categorical Shift Carry-Over Effect Test Practical Issues COMPARING TIME-TO-EVENT DATA Basic Concepts Exponential Model Cox's Proportional Hazards Model Weighted Log-Rank Test Practical Issues GROUP SEQUENTIAL METHODS Pocock's Test O'Brien and Fleming's Test Wang and Tsiatis' Test Inner Wedge Test Binary Variables Time-to-Event Data Alpha Spending Function Sample Size Re-Estimation Conditional Power Practical Issues COMPARING VARIABILITIES Comparing Intra-Subject Variabilities Comparing Intra-Subject CVs Comparing Inter-Subject Variabilities Comparing Total Variabilities Practical Issues BIOEQUIVALENCE TESTING Bioequivalence Criteria Average Bioequivalence Population Bioequivalence Individual Bioequivalence In Vitro Bioequivalence NONPARAMETRICS Violation of Assumptions One-Sample Location Problem Two-Sample Location Problem Test for Independence Practical Issues SAMPLE SIZE CALCULATION IN OTHER AREAS Dose Response Studies ANOVA with Repeated Measures Quality of Life Bridging Studies Vaccine Clinical Trials Appendix: Tables of Quantiles References Index

[1]  F. Wilcoxon.  Individual Comparisons by Ranking Methods , 1945 .

[2]  W. Kruskal,et al.  Use of Ranks in One-Criterion Variance Analysis , 1952 .

[3]  David R. Cox,et al.  A note on the sequential estimation of means , 1952, Mathematical Proceedings of the Cambridge Philosophical Society.

[4]  P. Armitage.  Tests for Linear Trends in Proportions and Frequencies , 1955 .

[5]  A. Stuart.  A TEST FOR HOMOGENEITY OF THE MARGINAL DISTRIBUTIONS IN A TWO-WAY CLASSIFICATION , 1955 .

[6]  Jerome Cornfield,et al.  A Statistical Problem Arising from Retrospective Studies , 1956 .

[7]  W. Haenszel,et al.  Statistical aspects of the analysis of data from retrospective studies of disease. , 1959, Journal of the National Cancer Institute.

[8]  N. Laubscher,et al.  Normalizing the Noncentral $t$ and $F$ Distributions , 1960 .

[9]  208. Note: A Note on the Paper Two Sequential Two-Sample Grouped Rank Tests with Application to Screening Experiments , 1964 .

[10]  P. Armitage,et al.  Repeated Significance Tests on Accumulating Data , 1969 .

[11]  J. Haybittle,et al.  Repeated assessment of results in clinical trials of cancer treatment. , 1971, The British journal of radiology.

[12]  Williams Da,et al.  A test for differences between treatment means when several dose levels are compared with a zero dose control. , 1971 .

[13]  D. A. Williams,et al.  The comparison of several dose levels with a zero dose control. , 1972, Biometrics.

[14]  S. George,et al.  Planning the size and duration of a clinical trial studying the time to some critical event. , 1974, Journal of chronic diseases.

[15]  A. Feinstein,et al.  Clinical biostatistics , 1974 .

[16]  W. G. Howe.  Approximate Confidence Limits on the Mean of X + Y Where X and Y Are Two Tabled Independent Random Variables , 1974 .

[17]  K. Gabriel,et al.  On closed testing procedures with special reference to ordered analysis of variance , 1976 .

[18]  C. Dunnett,et al.  Significance testing to establish equivalence between treatments, with special reference to data in the form of 2X2 tables. , 1977, Biometrics.

[19]  E Shirley,et al.  A non-parametric equivalent of Williams' test for contrasting increasing dose levels of a treatment. , 1977, Biometrics.

[20]  S. Pocock.  Group sequential methods in the design and analysis of clinical trials , 1977 .

[21]  Gary G. Koch,et al.  Average Partial Association in Three-way Contingency Tables: a Review and Discussion of Alternative Tests , 1978 .

[22]  H A Wendel,et al.  Randomization in clinical trials. , 1978, Science.

[23]  S. Holm.  A Simple Sequentially Rejective Multiple Test Procedure , 1979 .

[24]  P. O'Brien,et al.  A multiple testing procedure for clinical trials. , 1979, Biometrics.

[25]  Franklin A. Graybill,et al.  'Exact' Two-Sided Confidence Intervals on Nonnegative Linear Combinations of Variances. , 1980 .

[26]  N. Breslow,et al.  Statistical methods in cancer research. Vol. 1. The analysis of case-control studies. , 1981 .

[27]  An overview of FDA, IRBs and regulations. , 1981, IRB.

[28]  D. Schoenfeld.  The asymptotic properties of nonparametric tests for comparing survival distributions , 1981 .

[29]  M H Gail,et al.  Planning the duration of a comparative clinical trial with loss to follow-up and a period of continued observation. , 1981, Journal of chronic diseases.

[30]  J. Lachin.  Introduction to sample size determination and power analysis for clinical trials. , 1981, Controlled clinical trials.

[31]  Charles R. Buncher,et al.  Statistics in the Pharmaceutical Industry , 1981 .

[32]  L. Freedman.  Tables of the number of patients required in clinical trials using the logrank test. , 1982, Statistics in medicine.

[33]  W C Blackwelder,et al.  "Proving the null hypothesis" in clinical trials. , 1981, Controlled clinical trials.

[34]  P. McCullagh.  Quasi-Likelihood Functions , 1983 .

[35]  N. Tygstrup,et al.  The Randomized Clinical Trial and Therapeutic Decisions. , 1983 .

[36]  K. K. Lan,et al.  Discrete sequential boundaries for clinical trials , 1983 .

[37]  D. Rubin,et al.  The central role of the propensity score in observational studies for causal effects , 1983 .

[38]  D. Rubin,et al.  Reducing Bias in Observational Studies Using Subclassification on the Propensity Score , 1984 .

[39]  David G. Hoel,et al.  Type 1 error of trend tests in proportions and the design of cancer screens , 1984 .

[40]  A A Tsiatis,et al.  Exact confidence intervals following a group sequential test. , 1984, Biometrics.

[41]  C. Bulpitt,et al.  Clinical Trials—Issues and Approaches , 1984 .

[42]  V. Miké,et al.  Statistics in medical research : methods and issues, with applications in cancer research , 1984 .

[43]  J. Gart.  Approximate tests and interval estimation of the common relative risk in the combination of 2×2 tables , 1985 .

[44]  M. Palmer.  Clinical Trials: A Practical Approach , 1985 .

[45]  M Nurminen,et al.  Comparative analysis of two rates. , 1985, Statistics in medicine.

[46]  E. Gehan,et al.  Cancer Clinical Trials: Methods and Practice , 1985 .

[47]  L. Moses.  Statistical concepts fundamental to investigations. , 1985, The New England journal of medicine.

[48]  J W Tukey,et al.  Testing the statistical certainty of a response to increasing doses of a drug. , 1985, Biometrics.

[49]  M. Gail,et al.  Testing for qualitative interactions between treatment effects and patient subsets. , 1985, Biometrics.

[50]  M H Gail,et al.  Applicability of sample size calculations based on a comparison of proportions for use with the logrank test. , 1985, Controlled clinical trials.

[51]  J. Fleiss.  The design and analysis of clinical experiments , 1987 .

[52]  D. Spiegelhalter,et al.  A predictive approach to selecting the size of a clinical trial, based on subjective clinical opinion. , 1986, Statistics in medicine.

[53]  E. Lakatos,et al.  Sample size determination in clinical trials with time-dependent rates of losses and noncompliance. , 1986, Controlled clinical trials.

[54]  J M Lachin,et al.  Evaluation of sample size and power for analyses of survival with allowance for nonuniform patient entry, losses to follow-up, noncompliance, and stratification. , 1986, Biometrics.

[55]  A. Tsiatis,et al.  Approximately optimal one-parameter boundaries for group sequential trials. , 1987, Biometrics.

[56]  K Kim,et al.  Confidence intervals following group sequential tests in clinical trials. , 1987, Biometrics.

[57]  J M Nam,et al.  A simple approximation for calculating sample sizes for detecting linear trend in proportions. , 1987, Biometrics.

[58]  Laurence H. Baker,et al.  Clinical Trials: Design, Conduct, and Analysis , 1987 .

[59]  S. Chow,et al.  A new procedure for the estimation of variance components , 1988 .

[60]  R Simon,et al.  Sample size considerations for studies comparing survival curves using historical controls. , 1988, Journal of clinical epidemiology.

[61]  Steven G. Self,et al.  Power/Sample Size Calculations for Generalized Linear Models , 1988 .

[62]  Y. Hochberg.  A sharper Bonferroni procedure for multiple tests of significance , 1988 .

[63]  K K Lan,et al.  The B-value: a tool for monitoring data. , 1988, Biometrics.

[64]  S. Pocock,et al.  Stopping rules and estimation problems in clinical trials. , 1988, Statistics in medicine.

[65]  Carl M. Metzler,et al.  Biopharmaceutical statistics for drug development , 1988 .

[66]  P. Jacobsen.  Design and analysis of clinical trials. , 1988, Journal of dentistry.

[67]  E. Lakatos,et al.  Sample sizes based on the log-rank statistic in complex clinical trials. , 1988, Biometrics.

[68]  C. J. Adcock,et al.  A Bayesian Approach to Calculating Sample Sizes , 1988 .

[69]  W Insull,et al.  Statistical design of the Women's Health Trial. , 1988, Controlled clinical trials.

[70]  K Kim,et al.  Point estimation following group sequential tests. , 1989, Biometrics.

[71]  R. Simon,et al.  Optimal two-stage designs for phase II clinical trials. , 1989, Controlled clinical trials.

[72]  D. Kessler,et al.  The regulation of investigational drugs. , 1989, The New England journal of medicine.

[73]  M. Chang,et al.  Confidence intervals for a normal mean following a group sequential test. , 1989, Biometrics.

[74]  S. Young,et al.  p Value Adjustments for Multiple Tests in Multivariate Binomial Models , 1989 .

[75]  M. Kenward,et al.  Design and Analysis of Cross-Over Trials , 1989 .

[76]  P. Goodman,et al.  A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. , 1989, The New England journal of medicine.

[77]  M D Hughes,et al.  Practical problems in interim analyses, with particular regard to estimation. , 1989, Controlled clinical trials.

[78]  L J Emrich,et al.  Required duration and power determinations for historically controlled studies of survival times. , 1989, Statistics in medicine.

[79]  C. Farrington,et al.  Test statistics and sample size formulae for comparative binomial trials with null hypothesis of non-zero risk difference or non-unity relative risk. , 1990, Statistics in medicine.

[80]  Christopher Jennison,et al.  Statistical Approaches to Interim Monitoring of Medical Trials: A Review and Commentary , 1990 .

[81]  Statistical methodology in the pharmaceutical sciences. Edited by D. S. Berry. Marcel Dekker: New York. 1990, viii + 578 pp. 16 × 23 cm. ISBN: 0‐8247‐8117‐1. $125.00 , 1990 .

[82]  M Schumacher,et al.  Statistical analysis of quality of life data in cancer clinical trials. , 1990, Statistics in medicine.

[83]  S. Chow,et al.  TEST FOR TREATMENT EFFECT BASED ON BINARY DATA WITH RANDOM SAMPLE SIZES , 1990 .

[84]  T. Fleming.  Evaluation of active control trials in AIDS. , 1990, Journal of acquired immune deficiency syndromes.

[85]  Y Pawitan,et al.  Statistical interim monitoring of the Cardiac Arrhythmia Suppression Trial. , 1990, Statistics in medicine.

[86]  E. K. Harris,et al.  Survivorship Analysis for Clinical Studies , 1990 .

[87]  P. K. Tandon.  Applications of global statistics in analysing quality of life data. , 1990, Statistics in medicine.

[88]  J O'Quigley,et al.  Continual reassessment method: a practical design for phase 1 clinical trials in cancer. , 1990, Biometrics.

[89]  Shirley Dex,et al.  JR 旅客販売総合システム（マルス）における運用及び管理について , 1991 .

[90]  S. Dubey,et al.  Some thoughts on the one-sided and two-sided tests. , 1991, Journal of biopharmaceutical statistics.

[91]  M. Smith.  Statistical Issues in Drug Research and Development. , 1991 .

[92]  B. Spilker.  Guide to clinical trials , 1991 .

[93]  S. Green,et al.  Planned versus attained design in phase II clinical trials. , 1992, Statistics in medicine.

[94]  M. L. Mitchell,et al.  Medical Uses of Statistics , 1992 .

[95]  Bioequivalence revisited. , 1992, Statistics in medicine.

[96]  Steven G. Self,et al.  Power Calculations for Likelihood Ratio Tests in Generalized Linear Models , 1992 .

[97]  M. Chavance.  [Jackknife and bootstrap]. , 1992, Revue d'epidemiologie et de sante publique.

[98]  S. S. Young,et al.  Resampling-Based Multiple Testing: Examples and Methods for p-Value Adjustment , 1993 .

[99]  M P Becker,et al.  Marginal modeling of binary cross-over data. , 1993, Biometrics.

[100]  M D Hughes,et al.  Stopping guidelines for clinical trials with multiple treatments. , 1993, Statistics in medicine.

[101]  Interim analysis in the pharmaceutical industry. PMA Biostatistics and Medical Ad Hoc Committee on Interim Analysis. , 1993, Controlled clinical trials.

[102]  Gene Sogliero-Gilbert.  Drug safety assessment in clinical trials , 1993 .

[103]  W. Shih,et al.  Sample Size Reestimation for Triple Blind Clinical Trials , 1993 .

[104]  R. Temple.  Trends in Pharmaceutical Development , 1993 .

[105]  Nicholas T. Longford.  Regression analysis of multilevel data with measurement error , 1993 .

[106]  R Schall,et al.  On population and individual bioequivalence. , 1993, Statistics in medicine.

[107]  B W Turnbull,et al.  Sequential equivalence testing and repeated confidence intervals, with applications to normal and binary responses. , 1993, Biometrics.

[108]  J. Heyse,et al.  Reduction in burden of illness: a new efficacy measure for prevention trials. , 1994, Statistics in medicine.

[109]  P F Thall,et al.  An optimal three-stage design for phase II clinical trials. , 1994, Statistics in medicine.

[110]  S. Ellenberg,et al.  Statistical issues in designing clinical trials of aids treatments and vaccines , 1994 .

[111]  On statistical characteristics of quality of life assessment. , 1994, Journal of biopharmaceutical statistics.

[112]  D L DeMets,et al.  Interim analysis: the alpha spending function approach. , 1994, Statistics in medicine.

[113]  D A Follmann,et al.  Monitoring multi-armed trials. , 1994, Statistics in medicine.

[114]  V. Chinchilli,et al.  Extension to the use of tolerance intervals for the assessment of individual bioequivalence. , 1994, Journal of biopharmaceutical statistics.

[115]  D. Kessler,et al.  Faster evaluation of vital drugs. , 1995, Scientific American.

[116]  J H Shih,et al.  Sample size calculation for complex clinical trials with survival endpoints. , 1995, Controlled clinical trials.

[117]  J. Crowley,et al.  Design of the Prostate Cancer Prevention Trial (PCPT). , 1995, Controlled clinical trials.

[118]  I Olkin,et al.  Meta-analysis: reconciling the results of independent studies. , 1995, Statistics in Medicine.

[119]  A. Gould.  Planning and revising the sample size for a trial. , 1995, Statistics in Medicine.

[120]  J. Bryant,et al.  Incorporating toxicity considerations into the design of two-stage phase II clinical trials. , 1995, Biometrics.

[121]  P. Thall,et al.  Bayesian sequential monitoring designs for single-arm clinical trials with multiple outcomes. , 1995, Statistics in medicine.

[122]  J Röhmel,et al.  An adaptive method for establishing a dose-response relationship. , 1995, Statistics in medicine.

[123]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[124]  Statistical issues in quality-of-life assessment. , 1996, Journal of biopharmaceutical statistics.

[125]  Efficiency robust tests of independence in contingency tables with ordered classifications. , 1996, Statistics in medicine.

[126]  William H. Press,et al.  In: Numerical Recipes in Fortran 90 , 1996 .

[127]  Ji Zhang,et al.  Testing the Hypothesis that Matters for Multiple Primary Endpoints , 1996 .

[128]  R. Berger,et al.  Bioequivalence trials, intersection-union tests and equivalence confidence sets , 1996 .

[129]  V M Chinchilli,et al.  Design and analysis of intra-subject variability in cross-over experiments. , 1996, Statistics in medicine.

[130]  M R Conaway,et al.  Designs for phase II trials allowing for a trade-off between response and toxicity. , 1996, Biometrics.

[131]  H Quan,et al.  Assessing reproducibility by the within-subject coefficient of variation with random effects models. , 1996, Biometrics.

[132]  J O'Quigley,et al.  Continual reassessment method: a likelihood approach. , 1996, Biometrics.

[133]  Sven Eriksson.  PLANNING PHARMACEUTICAL CLINICAL TRIALS. BASIC STATISTICAL PRINCIPLES. , 1996 .

[134]  P F Thall,et al.  New statistical strategy for monitoring safety and efficacy in single-arm clinical trials. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[135]  A Agresti,et al.  A review of tests for detecting a monotone dose-response relationship with ordinal response data. , 1997, Statistics in medicine.

[136]  T. Louis,et al.  Unified frequentist and Bayesian testing of a precise hypothesis , 1997 .

[137]  W J Shih,et al.  Design for sample size re-estimation with interim data for double-blind clinical trials with binary outcomes. , 1997, Statistics in medicine.

[138]  L. Joseph,et al.  Bayesian sample size determination for normal means and differences between normal means , 1997 .

[139]  T. Chen,et al.  Optimal three-stage designs for phase II cancer clinical trials. , 1997, Statistics in medicine.

[140]  D. Lindley.  The choice of sample size , 1997 .

[141]  T. Pham-Gia,et al.  On Bayesian analysis, Bayesian decision theory and the sample size problem , 1997 .

[142]  Tu Dongsheng.  Two one-sided tests procedures in establishing therapeutic equivalence with binary clinical endpoints: fixed sample performances and sample size derformination , 1997 .

[143]  P. Westfall,et al.  Multiple Tests with Discrete Distributions , 1997 .

[144]  K Y Liang,et al.  Sample size calculations for studies with correlated observations. , 1997, Biometrics.

[145]  J. Whitehead,et al.  Bayesian decision procedures with application to dose-finding studies , 1997 .

[146]  M L Chen.  Individual bioequivalence--a regulatory update. , 1997, Journal of biopharmaceutical statistics.

[147]  Chikayuki Naito,et al.  Ethnic Factors in the Acceptability of Foreign Clinical Data , 1998 .

[148]  T T Chen,et al.  Optimal flexible designs in phase II clinical trials. , 1998, Statistics in medicine.

[149]  R. Kay.  Statistical Principles for Clinical Trials , 1998, The Journal of international medical research.

[150]  I. Chan,et al.  Exact power and sample size for vaccine efficacy studies , 1998 .

[151]  Guidance for Industry Providing Clinical Evidence of Effectiveness for Human Drug and Biological Products , 1998 .

[152]  S. D. Durham,et al.  A sequential design for maximizing the probability of a favourable response , 1998 .

[153]  Q. Liu.  An order-directed score test for trend in ordered 2 X K tables. , 1998, Biometrics.

[154]  J. Mesirov,et al.  Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. , 1999, Science.

[155]  S. Chow.  Individual Bioequivalence—A Review of the FDA Draft Guidance , 1999 .

[156]  Ludwig A. Hothorn,et al.  An exact Cochran-Armitage test for trend when dose-response shapes are a priori unknown , 1999 .

[157]  Frank Bretz,et al.  Evaluation of Animal Carcinogenicity Studies: Cochran‐Armitage Trend Test vs. Multiple Contrast Tests , 2000 .

[158]  Jeffrey R. Eisele,et al.  A Curve‐Free Method for Phase I Clinical Trials , 2000, Biometrics.

[159]  Masashi Goto,et al.  Statistical Approaches to Detecting Dose-Response Relationships , 2000 .

[160]  T Hyslop,et al.  A small sample confidence interval approach to assess individual bioequivalence. , 2000, Statistics in medicine.

[161]  S. Ruberg,et al.  Detecting dose response with contrasts. , 2000, Statistics in medicine.

[162]  J. Witte,et al.  On the relative sample size required for multiple comparisons. , 2000, Statistics in medicine.

[163]  Yi Tsong,et al.  Tests for Equivalence or Noninferiority Between Two Proportions , 2000 .

[164]  D. Mehrotra,et al.  Minimum risk weights for comparing treatments in stratified binomial trials. , 2000, Statistics in medicine.

[165]  C. Sander,et al.  Genomic medicine and the future of health care. , 2000, Science.

[166]  Philip H. Ramsey.  Nonparametric Statistical Methods , 1974, Technometrics.

[167]  Ash A. Alizadeh,et al.  Genomic-scale gene expression profiling of normal and malignant immune cells. , 2000, Current opinion in immunology.

[168]  KyungMann Kim.  Group Sequential Methods with Applications to Clinical Trials , 2001 .

[169]  Y. Benjamini,et al.  THE CONTROL OF THE FALSE DISCOVERY RATE IN MULTIPLE TESTING UNDER DEPENDENCY , 2001 .

[170]  J. Thomas,et al.  An efficient and robust statistical modeling approach to discover differentially expressed genes using genomic expression profiles. , 2001, Genome research.

[171]  W J Shih,et al.  Statistical properties of the traditional algorithm-based designs for phase I cancer clinical trials. , 2001, Biostatistics.

[172]  D J Sargent,et al.  A flexible design for multiple armed screening trials , 2001, Statistics in medicine.

[173]  W. Pan,et al.  How many replicates of arrays are required to detect gene expression changes in microarray experiments? A mixture model approach , 2002, Genome Biology.

[174]  A J Camm,et al.  Evaluation of Drug-Induced QT Interval Prolongation , 2001, Drug safety.

[175]  R. Gentleman,et al.  Global expression changes of constitutive and hormonally regulated genes during endometrial neoplastic transformation. , 2001, Gynecologic oncology.

[176]  Pierre R. Bushel,et al.  Assessing Gene Significance from cDNA Microarray Expression Data via Mixed Models , 2001, J. Comput. Biol..

[177]  R. Spang,et al.  Predicting the clinical status of human breast cancer by using gene expression profiles , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[178]  Frank Bretz,et al.  Detecting dose–response using contrasts: asymptotic power and sample size determination for binomial data , 2002, Statistics in medicine.

[179]  Wei Pan,et al.  A comparative review of statistical methods for discovering differentially expressed genes in replicated microarray experiments , 2002, Bioinform..

[180]  S. Chow,et al.  Statistics in Drug Research: Methodologies and Recent Developments , 2002 .

[181]  Shein-Chung Chow,et al.  ASSESSING SENSITIVITY AND SIMILARITY IN BRIDGING STUDIES , 2002, Journal of biopharmaceutical statistics.

[182]  John D. Storey.  A direct approach to false discovery rates , 2002 .

[183]  Michael A. Proschan,et al.  A Unified Theory of Two-Stage Adaptive Designs , 2002 .

[184]  Dmitri V Zaykin,et al.  Multiple tests for genetic effects in association studies. , 2002, Methods in molecular biology.

[185]  G A Whitmore,et al.  Power and sample size for DNA microarray studies , 2002, Statistics in medicine.

[186]  Sample size calculation in bioequivalence trials. , 2002, Journal of pharmacokinetics and pharmacodynamics.

[187]  J. Shaffer.  Multiplicity, directional (type III) errors, and the null hypothesis. , 2002, Psychological methods.

[188]  S. Dudoit,et al.  STATISTICAL METHODS FOR IDENTIFYING DIFFERENTIALLY EXPRESSED GENES IN REPLICATED cDNA MICROARRAY EXPERIMENTS , 2002 .

[189]  P. Meier.  TIIE BIGGEST PUBLIC IIEALTH EXPERIMENT EVER : The 1954 Field Trial of the Salk Poliomyelitis Vaccine , 2002 .

[190]  L. Wasserman,et al.  Operating characteristics and extensions of the false discovery rate procedure , 2002 .

[191]  S. Chow,et al.  Reproducibility probability in clinical trials , 2002, Statistics in medicine.

[192]  R. W. Doerge,et al.  Calculation of the minimum number of replicate spots required for detection of significant gene expression fold change in microarray experiments , 2002, Bioinform..

[193]  James S. Babb and Andre´ Rogatko.  Bayesian Methods for Cancer Phase I Clinical Trials , 2003 .

[194]  Yongchao Ge.  Resampling-based Multiple Testing for Microarray Data Analysis , 2003 .

[195]  S. Chow,et al.  STATISTICAL TESTS FOR POPULATION BIOEQUIVALENCE , 2003 .

[196]  S. Chow,et al.  In vitro bioequivalence testing , 2003, Statistics in medicine.

[197]  Minge Xie,et al.  Design and Analysis of Bioavailability and Bioequivalence Studies , 2003 .

[198]  John D. Storey,et al.  SAM Thresholding and False Discovery Rates for Detecting Differential Gene Expression in DNA Microarrays , 2003 .

[199]  S. Dudoit,et al.  Multiple Hypothesis Testing in Microarray Experiments , 2003 .

[200]  John D. Storey.  The positive false discovery rate: a Bayesian interpretation and the q-value , 2003 .

[201]  Vaccine Clinical Trials , 2003 .

[202]  E. Korn,et al.  An Example of Slow Convergence of the Bootstrap in High Dimensions , 2004 .

[203]  C. Robert,et al.  Optimal Sample Size for Multiple Testing : the Case of Gene Expression Mi roarraysPeter , 2004 .

[204]  John D. Storey,et al.  Strong control, conservative point estimation and simultaneous conservative consistency of false discovery rates: a unified approach , 2004 .

[205]  Xiangqin Cui,et al.  How Many Mice and How Many Arrays? Replication in Mouse cDNA Microarray Experiments , 2004 .

[206]  S. Chow,et al.  Analysis of clinical data with breached blindness , 2004, Statistics in medicine.

[207]  A Note on Sample Size Determination for Bioequivalence Studies with Higher-Order Crossover Designs , 1997, Journal of Pharmacokinetics and Biopharmaceutics.

[208]  Ronnie Driver,et al.  Biostatistics: a Methodology for the Health Sciences , 2005 .

[209]  Donald J. Schuirmann.  A comparison of the Two One-Sided Tests Procedure and the Power Approach for assessing the equivalence of average bioavailability , 1987, Journal of Pharmacokinetics and Biopharmaceutics.

[210]  K. Phillips.  Power of the two one-sided tests procedure in bioequivalence , 1990, Journal of Pharmacokinetics and Biopharmaceutics.

[211]  Shein-Chung Chow,et al.  A Hybrid Bayesian Adaptive Design for Dose Response Trials , 2005, Journal of biopharmaceutical statistics.

[212]  Sin-Ho Jung,et al.  Sample size for FDR-control in microarray data analysis , 2005, Bioinform..

[213]  N. Abrouk.  Book Review: Design and analysis of clinical trials, 2nd edition , 2005 .

[214]  Shein-Chung Chow,et al.  Sample size determination for the two one-sided tests procedure in bioequivalence , 1992, Journal of Pharmacokinetics and Biopharmaceutics.

[215]  S. Chow,et al.  A Bayesian Approach on Sample Size Calculation for Comparing Means , 2005, Journal of biopharmaceutical statistics.

[216]  Sin-Ho Jung,et al.  Sample size calculation for multiple testing in microarray data analysis. , 2005, Biostatistics.

[217]  S. Chow,et al.  Power and Sample Size for Dose Response Studies , 2006 .

[218]  S. Chow,et al.  A Related Problem in Bioavailability/Bioequivalence Studies — Estimation of the Intrasubject Variability With a Common CV , 2007 .

[219]  Lilly Q Yue,et al.  Statistical and Regulatory Issues with the Application of Propensity Score Analysis to Nonrandomized Medical Device Clinical Studies , 2007, Journal of biopharmaceutical statistics.